Jump to Main Contents
研究所ロゴ

Home > Organization > Divisions and Independent Research Units > Group for Independent Research Unit > Laboratory of Cancer RNA Research

Laboratory of Cancer RNA Research

Our News

Oct 13, 2021 Our first paper is out in Nature!

Collaboration with Dr. Savvas Savvides Group at Ghent university/VIB-UGent Center for Inflammation Research

De Munck S, Provost M, Kurikawa M, Omori I, Mukohyama J, Felix J, Bloch Y, Abdel-Wahab O, Bazen F, Yoshimi A, Savvides SN. Structural basis of cytokine-mediated activation of ALK family receptors. Nature, in press. doi.org/10.1038/s41586-021-03959-5.

Press Release
Oct 5, 2021 Our research proposal was accepted by AMED (Science and Technology Platform Program for Advanced Biological Medicine; co-PI: Akihide Yoshimi)
Oct 1,2021 Kazuki Nishimura joined us as an External Research Staff!
Sep 27, 2021 Michiko Kurikawa was selected for the JSPS Research Fellowships for Young Scientists (DC1)!
Sep 17, 2021 Kota Otsuki joined us as a trainee!
Sep 12, 2021 Akihide Yoshimi had an invited talk at the 1st JCA-AACR Precision Cancer Medicine International Conference
 Sep 1, 2021 Guzhanuer Ailiken joined us as a postdoc!
Aug 16, 2021 Atsuhito Nakayama joined us as a PhD student!
Jul 30, 2021 Our research proposal was accepted by Takeda Science Foundation (Takeda hosho Medical Research grant; PI: Akihide Yoshimi)
Jul 6, 2021 Akihide Yoshimi had an invited talk at the 39th Sapporo International Cancer Symposium
Jul 6, 2021 Michiko Kurikawa and Hirofumi Yamauchi gave poster presentations at the 139th Sapporo International Cancer Symposium
Apr 5, 2021 Our research proposal was accepted by JSPS (Grant-in-Aid for Scientific Research (A); PI: Akihide Yoshimi)
Apr 1, 2021 Hirofumi Yamauchi and Michiko Kurikawa started his/her PhD courses!
Apr 1, 2021 Ikuko Omori joined us as a postdoc!
Jan 15, 2021 Our research proposal was accepted by AMED (Japan-Canada Joint Grant: SICORP ; PI: Akihide Yoshimi)
Jan 1, 2021 Takahiro Nishino joined us as a trainee!
Dec 1, 2020 Hanaako Nakamura Joined us as a technician!
Nov 13, 2020 Akihide Yoshimi had an invited talk at the 7th Cancer Epigenomics Symposium
Nov 12, 2020 Akihide Yoshimi was selected for the Leukemia & Lymphoma Society’s CDP (Special Fellow) Achievement Award!
Nov 1, 2021 Atsuro Oishi joined us as an External Research Staff!
Oct 16, 2020 Xiaohui Song joined us as a technician!
Oct 1, 2020 Akihide Yoshimi presented our recent work at the 79th Japanese Cancer Association Annual Meeting
Oct 1, 2020 Hirofumi Yamauchi joined us as an External Resarch Staff!
Aug 18, 2020 Our research proposal was accepted by JSPS (Home-Returning Researcher Development Research; PI: Akihide Yoshimi)
Aug 1, 2020 Michiko Kurikawa joined us as an External Resarch Staff!
Aug 18, 2020 Our research proposal was accepted by JSPS (Home-Returning Researcher Development Research; PI: Akihide Yoshimi)
Jul 1, 2020 Birthday of Cancer RNA Research Unit!! Akihide Yoshimi joined as a Section Head!



Our Research Interest


Our studies have been focused on how RNA processing including RNA splicing is altered in cancer and functionally drives cancer initiation and maintenance. The advent of high-throughput transcriptome sequencing has provided a wealth of information on RNA splicing on a genome-wide scale. It is now understood that > 95% of human genes are subject to alternative splicing. RNA splicing is considered to be a major mediator of proteome diversity through its ability to generate multiple transcripts with differing amino acid sequences from a single gene. The discovery of recurrent mutations in components of the RNA-splicing machinery in 2011 further highlighted the importance of aberrant splicing in cancer as well as a potential therapeutic vulnerability for cells bearing these mutations. Despite the major advances in our understanding of the genomics, molecular biology and therapeutic implications of altered RNA processing in cancer, the full contribution of aberrant RNA splicing to cancer pathogenesis has not been fully elucidated. Our aim is to contribute to the full understanding of the pathogenic roles of altered RNA processing in a variety of cancers and to the development of therapeutically efficacious and safe strategies to improve the outcome of cancer patients.